Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Free Cash Flow (2018 - 2025)

BioNexus Gene Lab's Free Cash Flow history spans 8 years, with the latest figure at -$1.2 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 31.03% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached -$2.8 million, up 16.8%, while the annual FY2024 figure was -$2.5 million, 24.83% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$1.2 million at BioNexus Gene Lab, down from -$759366.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $481728.0 in Q4 2021 and bottomed at -$1.8 million in Q3 2024.
  • The 5-year median for Free Cash Flow is -$116620.0 (2023), against an average of -$353182.9.
  • The largest annual shift saw Free Cash Flow soared 111.72% in 2021 before it plummeted 1665.65% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $481728.0 in 2021, then dropped by 1.04% to $476739.0 in 2022, then crashed by 264.34% to -$783463.0 in 2023, then surged by 109.47% to $74181.0 in 2024, then crashed by 1775.56% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Free Cash Flow are -$1.2 million (Q3 2025), -$759366.0 (Q2 2025), and -$833124.0 (Q1 2025).